81 FR 66284 - Statement of Organization, Functions, and Delegations of Authority
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Centers for Disease Control and Prevention Federal Register Volume 81, Issue 187 (September 27, 2016)
Centers for Disease Control and Prevention
Federal Register Volume 81, Issue 187 (September 27, 2016)
| Page Range | 66284-66285 | |
| FR Document | 2016-23212 |
[Federal Register Volume 81, Number 187 (Tuesday, September 27, 2016)] [Notices] [Pages 66284-66285] From the Federal Register Online [www.thefederalregister.org] [FR Doc No: 2016-23212] ----------------------------------------------------------------------- DEPARTMENT OF HEALTH AND HUMAN SERVICES Centers for Disease Control and Prevention Statement of Organization, Functions, and Delegations of Authority Part C (Centers for Disease Control and Prevention) of the Statement of [[Page 66285]] Organization, Functions, and Delegations of Authority of the Department of Health and Human Services (45 FR 67772-76, dated October 14, 1980, and corrected at 45 FR 69296, October 20, 1980, as amended most recently at 81 FR 54091-54094, dated August 15, 2016) is amended to reflect the reorganization of the Office of the Director, National Center for Emerging and Zoonotic Infectious Diseases, Office of Infectious Diseases, Centers for Disease Control and Prevention. Section C-B, Organization and Functions, is hereby amended as follows: Insert item (10) ensures compliance with and manages the infectious diseases Clinical Laboratory Improvement Amendments (CLIA) unit within the Office of Infectious Diseases (CV), and renumber remaining items accordingly. Delete item (5) ensures scientific quality and ethical and regulatory compliance of center activities within the National Center for Emerging and Zoonotic Infectious Diseases (CVL), Office of the Director (CVL1), and renumber remaining items accordingly. Sherri Berger, Chief Operating Officer, Centers for Disease Control and Prevention. [FR Doc. 2016-23212 Filed 9-26-16; 8:45 am] BILLING CODE 4160-18-P
![66284 Federal Register / Vol. 81, No. 187 / Tuesday, September 27, 2016 / Notices
related adverse events, contaminated surveillance data into evidence-based partners and the public on vaccine
medical products and devices, and policies and targeted, innovative and safety concerns.
adverse drug events; (7) communicates collaborative interventions. Epidemiology Research and
the results of response activities with Innovations Branch (CVLDG). (1)
Immunization Safety Office (CVLDE).
Federal and state agencies, healthcare Identifies and evaluates the efficacy of
Assesses the safety of new and currently
providers, and the public, with interventions to prevent HAI and related
available vaccines received by children,
recommendations to prevent similar adverse events or medical errors across
adolescents and adults using a variety of the spectrum of healthcare delivery sites
adverse events in the future; and (8) strategies: (1) Conducts ongoing
provides leadership and expert including acute and long-term inpatient
surveillance for the timely detection of care, dialysis, and ambulatory settings;
consultation, guidance, and technical
possible adverse events following (2) identifies gaps in HAI-related
support to and collaborates with other
immunization (AEFI) in collaboration knowledge, and conducts prevention
CDC CIOs and divisions, other HHS
with the Food and Drug Administration research through the Prevention
Operating Divisions, and extramural
(FDA), through coordination and Epicenters cooperative agreements
domestic partners, on the epidemiology,
prevention, and control of HAI, AR, and management of the Vaccine Adverse program and Safety and Healthcare
related adverse events; (9) implements Event Reporting System, the national Epidemiology Prevention Research
state activities to prevent HAI and AR reporting system that acts as an early- Development research contracts; (3)
across healthcare; and (10) leads CDC warning system to detect health conducts and supports research and
activities to promote antimicrobial conditions that may be associated with evaluates impact of public health
stewardship in all healthcare settings. immunization; (2) coordinates, further practices to prevent HAI, antimicrobial
develops, maintains and directs resistance, and related adverse events;
Surveillance Branch (CVLDD). (1)
activities of the Vaccine Safety Datalink (4) improves methods and enables wider
Monitors and evaluates on the national
(VSD), a collaborative effort with use of clinical performance
level the extent, distribution, and
integrated healthcare organizations, to measurements by healthcare facilities
impact of HAI, antimicrobial use and
conduct surveillance and investigate and public health entities for specific
resistance, adverse drug events,
possible AEFI to assess causality and interventions and prevention strategies
healthcare worker safety events, and designed to safeguard patients and
adherence to clinical processes and determine risk factors; (3) conducts
epidemiologic research on causality of healthcare workers from risk exposures
intervention programs designed to and adverse outcomes through
prevent or control adverse exposures or AEFI using the VSD and other data
sources, and provides national estimates collaborations with extramural partners;
outcomes in healthcare; (2) provides (5) conducts applied research to identify
services, including leadership, of incidence of AEFI and background
rates of health conditions; (4) leads the and develop innovative methods to
consultation, and analysis support, for detect and monitor HAI and
statistical methods and analysis to nation in developing biostatistical
methods for research of AEFI using large antimicrobial resistance; (6) conducts
investigators in the branch, division, special studies to identify key risk
and other organizations responsible for linked databases and other data sources,
and shares methods for use by other factors for and provides national
surveillance, research studies, and estimates of targeted, healthcare-
prevention and control of HAI and other Agencies and public and private
entities; (5) conducts clinical research to associated adverse events, antimicrobial
healthcare-associated adverse events; (3) use and resistance patterns, and the
works with the Centers for Medicare identify causes of adverse events after
immunization, specific populations extent to which prevention and control
and Medicaid Services and other safeguards are in use to protect at-risk
partners to develop new metrics and susceptible to specific adverse events,
and prevention strategies through the patients across the spectrum of
support maintenance of National healthcare delivery sites; (7) develops
Quality Forum-approved metrics; (4) Clinical Immunization Safety
Assessment network, a national network new ways to assess the impact of HAI
collaborates with public and private prevention programs; (8) conducts
sector partners to further standardize, of medical research centers, and other
efforts; (6) applies findings from analysis of the return on investment and
integrate, and streamline systems by costs related to prevention efforts and
which healthcare organizations collect, epidemiologic and clinical studies to
develop strategies for prevention of impact of HAI prevention programs; and
manage, analyze, report, and respond to (9) works with the Emerging Infections
data on clinical guideline adherence, AEFI; (7) provides global consultation
and leadership for the development, Program (EIP) and other partners to
HAI, including transmission of multi- identify emerging issues.
drug resistant organisms, and other HAI; use, and interpretation of vaccine safety
(5) coordinates, further develops, surveillance systems, and for the Sherri Berger,
enables wider use, and maintains NHSN development of shared definitions of Chief Operating Officer, Centers for Disease
to obtain scientifically valid clinical specific health outcomes through Control and Prevention.
performance indices that promote participation in the Brighton [FR Doc. 2016–23213 Filed 9–26–16; 8:45 am]
healthcare quality and value at the Collaboration and other international BILLING CODE 4160–18–P
facility, state, and national levels; (6) organizations; (8) provides data for
develops and implements new NHSN action to HHS, the Advisory Committee
modules and provides enrollment and on Immunization Practices, the FDA’s DEPARTMENT OF HEALTH AND
user support for NHSN; (7) improves Vaccine and Related Biological Products HUMAN SERVICES
asabaliauskas on DSK3SPTVN1PROD with NOTICES
surveillance systems by utilizing new Advisory Committee, Health Resources
technology; (8) generates and provides and Services Administration’s Advisory Centers for Disease Control and
NHSN surveillance reports and Commission on Childhood Vaccines, Prevention
analyses, which include collaborative and collaborators around the globe
Statement of Organization, Functions,
analytic projects with partners; and (9) including the WHO Global Advisory
and Delegations of Authority
leads CDC’s national adverse drug Committee on Vaccine Safety; and (9)
events surveillance activities and seeks provides timely, accurate Part C (Centers for Disease Control
to translate population-based communication and education to and Prevention) of the Statement of
VerDate Sep<11>2014 17:08 Sep 26, 2016 Jkt 238001 PO 00000 Frm 00032 Fmt 4703 Sfmt 4703 E:\FR\FM\27SEN1.SGM 27SEN1](https://thefederalregister.org/doc/81_FR_66471/page/1.svg)
![Federal Register / Vol. 81, No. 187 / Tuesday, September 27, 2016 / Notices 66285
Organization, Functions, and Office of the Director (CVL1), and the voluntary acknowledgment of
Delegations of Authority of the renumber remaining items accordingly. paternity would include the minimum
Department of Health and Human requirements of the affidavit specified
Sherri Berger,
Services (45 FR 67772–76, dated by the Secretary under section 452(a)(7)
October 14, 1980, and corrected at 45 FR Chief Operating Officer, Centers for Disease
Control and Prevention.
and give full faith and credit to such an
69296, October 20, 1980, as amended affidavit signed in any other State
most recently at 81 FR 54091–54094, [FR Doc. 2016–23212 Filed 9–26–16; 8:45 am]
according to its procedures. The State
dated August 15, 2016) is amended to BILLING CODE 4160–18–P
must provide that, before a mother and
reflect the reorganization of the Office of putative father can sign a voluntary
the Director, National Center for acknowledgement of paternity, the
Emerging and Zoonotic Infectious DEPARTMENT OF HEALTH AND
HUMAN SERVICES mother and putative father must be
Diseases, Office of Infectious Diseases, given notice, orally and in writing of the
Centers for Disease Control and Administration for Children and alternatives to, the legal consequences
Prevention. of, and the rights (including any rights,
Families
Section C–B, Organization and if one parent is a minor, due to minority
Functions, is hereby amended as Proposed Information Collection status) and responsibilities of
follows: Activity; Comment Request Proposed acknowledging paternity. The affidavits
Insert item (10) ensures compliance Projects: will be used by hospitals, birth record
with and manages the infectious
agencies, and other entities participating
diseases Clinical Laboratory Title: Voluntary Acknowledgement of
in the voluntary paternity establishment
Improvement Amendments (CLIA) unit Paternity and Required Data Elements
program to collect information from the
within the Office of Infectious Diseases for Paternity Establishment Affidavits.
OMB No.: 0970–0171. parents of nonmarital children.
(CV), and renumber remaining items
accordingly. Description: Section 466(a)(5)(C) of Respondents: The parents of
Delete item (5) ensures scientific the Social Security Act requires States nonmarital children and State and
quality and ethical and regulatory to enact laws ensuring a simple civil Tribal IV–D agencies, hospitals, birth
compliance of center activities within process for voluntarily acknowledging record agencies and other entities
the National Center for Emerging and paternity via an affidavit. The participating in the voluntary paternity
Zoonotic Infectious Diseases (CVL), development and use of an affidavit for establishment program.
ANNUAL BURDEN ESTIMATES
Number of
Number of Average
responses per Total burden
Instrument respondents/ burden hours
respondent/ hours
partner per response
partner
Training ............................................................................................................ 130,330 1 1 130,300
Paternity Acknowledgment Process ................................................................ 2,606,596 1 0.17 443,121
Data Elements ................................................................................................. 54 1 1 54
Ordering Brochures ......................................................................................... 2,606,596 1 .08 208,528
Estimated Total Annual Burden practical utility; (b) the accuracy of the Assistant Secretary for Health, Office of
Hours: 782,003. agency’s estimate of the burden of the the Secretary, U.S. Department of Health
In compliance with the requirements proposed collection of information; (c) and Human Services.
of the Paperwork Reduction Act of 1995 the quality, utility, and clarity of the ACTION: Notice.
(Pub. L. 104–13, 44 U.S.C. Chap 35) information to be collected; and (d)
Paperwork Reduction Act of 1995, the ways to minimize the burden of the SUMMARY: As stipulated by the Federal
Administration for Children and collection of information on Advisory Committee Act (FACA), the
Families is soliciting public comment respondents, including through the use U.S. Department of Health and Human
on the specific aspects of the of automated collection techniques or Services (HHS) is hereby giving notice
information collection described above. other forms of information technology. that a meeting of the 2018 Physical
Copies of the proposed collection of Consideration will be given to Activity Guidelines Advisory
information can be obtained and comments and suggestions submitted Committee (2018 PAGAC or Committee)
comments may be forwarded by writing within 60 days of this publication. will be held. This meeting will be open
to the Administration for Children and to the public.
Robert Sargis,
Families, Office of Planning, Research
Reports Clearance Officer. DATES: The meeting will be held on
and Evaluation, 330 C Street SW.,
Washington DC 20201. Attn: ACF [FR Doc. 2016–23274 Filed 9–26–16; 8:45 am] October 27, 2016, from 2:15 p.m. E.D.T.
Reports Clearance Officer. Email BILLING CODE 4184–01–P to 5 p.m. E.D.T. and on October 28,
address: infocollection@acf.hhs.gov. All 2016, from 8:00 a.m. E.D.T. to 3:30 p.m.
asabaliauskas on DSK3SPTVN1PROD with NOTICES
requests should be identified by the title E.D.T.
of the information collection. DEPARTMENT OF HEALTH AND ADDRESSES: The meeting will be
The Department specifically requests HUMAN SERVICES accessible by webcast on the Internet or
comments on: (a) Whether the proposed by attendance in-person. For in-person
Meeting of the 2018 Physical Activity
collection of information is necessary participants, the meeting will take place
Guidelines Advisory Committee
for the proper performance of the in the National Institutes of Health
functions of the agency, including AGENCY: Office of Disease Prevention (NIH) Masur Auditorium, NIH Clinical
whether the information shall have and Health Promotion, Office of the Center, Building 10. The facility is
VerDate Sep<11>2014 17:08 Sep 26, 2016 Jkt 238001 PO 00000 Frm 00033 Fmt 4703 Sfmt 4703 E:\FR\FM\27SEN1.SGM 27SEN1](https://thefederalregister.org/doc/81_FR_66471/page/2.svg)
Document Created: 2016-09-27 01:19:01
Document Modified: 2016-09-27 01:19:01
| Category | Regulatory Information | |
| Collection | Federal Register | |
| sudoc Class | AE 2.7: GS 4.107: AE 2.106: | |
| Publisher | Office of the Federal Register, National Archives and Records Administration | |
| Section | Notices | |
| FR Citation | 81 FR 66284 |
2025 Federal Register | Disclaimer | Privacy Policy
USC | CFR | eCFR